David B. Cahn

David B. Cahn

Auto-generated profile, based on publicly available information

David B. Cahn

Department of Urology, Einstein Healthcare Network, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2017 in Cancer
Verified
Journal Article
Open access
PDF file
DCDavid B. Cahn
David B. Cahn
EHElizabeth A. Handorf
Elizabeth A. Handorf
EGEric M. Ghiraldi
Eric M. Ghiraldi
BRBenjamin T. Ristau
Benjamin T. Ristau
DGDaniel M. Geynisman
Daniel M. Geynisman
MSMarc C. Smaldone
Marc C. Smaldone
BACKGROUND: The current study was performed to examine temporal trends and compare overall survival (OS) in patients undergoing radical cystectomy (RC) or bladder‐preservation therapy (BPT) for muscle‐invasive urothelial carcinoma of the bladder.METHODS: The authors reviewed the National Cancer Data Base to identify patients with AJCC stage II to III urothelial carcinoma of the bladder from 2004 through 2013. Patients receiving BPT were stratified as having received any external‐beam radiotherapy (any XRT), definitive XRT (50‐80 grays), and definitive XRT with chemotherapy (CRT). Treatment trends and OS outcomes for the BPT and RC cohorts were evaluated using Cochran‐Armitage tests, unadjusted Kaplan‐Meier curves, adjusted Cox multivariate regression, and propensity score matching, using increasingly stringent selection criteria.RESULTS: A total of 32,300 patients met the inclusion criteria and were treated with RC (22,680 patients) or BPT (9620 patients). Of the patients treated with BPT, 26.4% (2540 patients) and 15.5% (1489 patients), respectively, were treated with definitive XRT and CRT. Improved OS was observed for RC in all groups. After adjustments with more rigorous statistical models controlling for confounders and with more restrictive BPT cohorts, the magnitude of the OS benefit became attenuated on multivariate (any XRT: hazard ratio [HR], 2.115 [95% confidence interval [95% CI], 2.045‐2.188]; definitive XRT: HR, 1.870 [95% CI, 1.773‐1.972]; and CRT: HR, 1.578 [95% CI, 1.474‐1.691]) and propensity score (any XRT: HR, 2.008 [95% CI, 1.871‐2.154]; definitive XRT: HR, 1.606 [95% CI, 1.453‐1.776]; and CRT: HR, 1.406 [95% CI, 1.235‐1.601]) analyses.CONCLUSIONS: In the National Cancer Data Base, receipt of BPT was associated with decreased OS compared with RC in patients with stage II to III urothelial carcinoma. Increasingly stringent definitions of BPT and more rigorous statistical methods adjusting for selection biases attenuated observed survival differences. Cancer 2017;123:4337‐45. © 2017 American Cancer Society.

12 September 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
BRBenjamin T Ristau
Benjamin T Ristau
EHElizabeth A. Handorf
Elizabeth A. Handorf
DCDavid B. Cahn
David B. Cahn
AKAlexander Kutikov
Alexander Kutikov
RURobert G. Uzzo
Robert G. Uzzo
MSMarc C. Smaldone
Marc C. Smaldone

1 December 2017 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
DCDavid B. Cahn
David B. Cahn
EHElizabeth Handorf
Elizabeth Handorf
BRBenjamin T. Ristau
Benjamin T. Ristau
DGDaniel M. Geynisman
Daniel M. Geynisman
JSJay Simhan
Jay Simhan
MSMarc C. Smaldone
Marc C. Smaldone

1 October 2016 in Urology
Verified
Journal Article
Closed access
DCDavid B. Cahn
David B. Cahn
BRBenjamin T. Ristau
Benjamin T. Ristau
EGEric M. Ghiraldi
Eric M. Ghiraldi
TCThomas M. Churilla
Thomas M. Churilla
DGDaniel M. Geynisman
Daniel M. Geynisman
MSMarc C. Smaldone
Marc C. Smaldone

1 July 2015 in Current Urology
Verified
Journal Article
Open access
PDF file
DCDavid B. Cahn
David B. Cahn
CRCurtis P. Ross
Curtis P. Ross
EDElliot P. Dubowitch
Elliot P. Dubowitch
MPMichelle L. Persun
Michelle L. Persun
PGPhilip C. Ginsberg
Philip C. Ginsberg
RHRichard C. Harkaway
Richard C. Harkaway
Objectives: To perform a retrospective analysis evaluating factors that may predict which men with elevated post-void residuals (PVRs) that were at increased risk to develop acute urinary retention (AUR). Methods: We retrospectively analyzed the records of 44 male patients who had 2 consecutive PVRs greater than 100 ml over a 6-month period. Using regression analysis, we evaluated patient's age, PVR volume, prostate specific antigen (PSA) and transrectal ultrasound prostate volume with respect to development of AUR over 24 months. Results: Of the 44 patients, 4 developed AUR. When all factors were considered, prostate volume was determined to be the only that was statistically significant (p = 0.003). A 1-SD increase in prostate volume (12 ml) led to a 19.6% increased risk of developing AUR. There was a strong correlation between PSA and prostate volume (0.787). A regression analysis was then repeated excluding prostate volume. PSA then became a statistically significant predictor of AUR (p = 0.007). A 1-SD increase in PSA (1.377 ng/ml) increased the patients' risk of developing AUR by 12.3%. Conclusion: In men with an elevated PVR, increased transrectal ultrasound prostate volume or PSA may help predict which patients have an elevated risk of developing AUR within the next 24 months. This information may influence which patients need early surgical intervention versus medical therapy.

1 October 2014 in Current Urology
Verified
Journal Article
Closed access
PDF file
EDElliot Dubowitch
Elliot Dubowitch
DCDavid Cahn
David Cahn
CRCurtis Ross
Curtis Ross
AHAli Husain
Ali Husain
RHRichard Harkaway
Richard Harkaway
PGPhilip Ginsberg
Philip Ginsberg
Pelvic organ prolapse can affect urinary tract function by reducing flow rates and increasing post void residual urine volumes secondary to outlet obstruction. If the diagnosis is missed or left untreated, pelvic organ prolapse can lead to acute renal injury, chronic renal failure or even end stage renal disease. Herein, we present a case of a patient who presented to Albert Einstein Medical Center in Philadelphia, PA with urinary retention and acute kidney injury secondary to complete uterine prolapse, also referred to as procidentia.